Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 4/20 | 0.55 |
| ▸ | DRD4 | P21917 | 4/20 | 0.55 |
| ▸ | DRD3 | P35462 | 4/20 | 0.55 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.49 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.49 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2804366 | 1.00 | DRD2 (0.55) | DRD2DRD4DRD3ITGB3ITGA2B | |
| SCHEMBL15922802 | 1.00 | DRD2 (0.55) | DRD2DRD4DRD3ITGB3ITGA2B | |
| SCHEMBL13483527 | 1.00 | DRD2 (0.55) | DRD2DRD4DRD3ITGB3ITGA2B | |
| SCHEMBL6849781 | 0.98 | DRD2 (0.57) | DRD2DRD4DRD3ITGB3ITGA2B | |
| SCHEMBL2470401 | 0.91 | DRD2 (0.59) | DRD2DRD4DRD3KCNH2L3MBTL1 | |
| Bromide SCHEMBL13519325 | 0.89 | DRD2 (0.57) | DRD2DRD4DRD3KCNH2L3MBTL1 | |
| SCHEMBL9011831 | 0.89 | DRD2 (0.65) | DRD2DRD4DRD3KCNH2L3MBTL1 | |
| SCHEMBL9011652 | 0.89 | DRD2 (0.65) | DRD2DRD4DRD3KCNH2L3MBTL1 | |
| SCHEMBL3805304 | 0.87 | DRD2 (0.68) | DRD2DRD4DRD3KCNH2L3MBTL1 | |
| SCHEMBL13073304 | 0.87 | ITGB3 (0.47) | DRD2DRD4DRD3ITGB3ITGA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2925804-B1 | COPOLYMERS OF POLYAMINOPOLYOLEFINS AND POLYANHYDRIDES | CHEVRON ORONITE CO (US) | 2019-02-20 | — | — | EP | disclosed |
| US-9243203-B2 | Copolymers of polyaminopolyolefins and polyanhydrides and methods of their preparation | CHEVRON ORONITE COMPANY LLC (US) | 2016-01-26 | — | — | US | disclosed |
| US-20140155308-A1 | COPOLYMERS OF POLYAMINOPOLYOLEFINS AND POLYANHYDRIDES AND METHODS OF THEIR PREPARATION | CHEVRON ORONITE COMPANY LLC (US) | 2014-06-05 | — | — | US | disclosed |
| US-8450348-B2 | Such as 3-[6-(4-Chloro-phenoxy)-hexylamino]-4-(pyridin-4-ylamino)-cyclobut-3-ene-1,2-dione; cancer, tumors; reduced side effects | FORMA TM, LLC (US) | 2013-05-28 | — | — | US | disclosed |
| EP-2096107-A1 | Derivatives of squaric acid with anti-proliferative activity | GPC Biotech AG (DE) | 2009-09-02 | — | — | EP | disclosed |
| EP-1674457-B1 | Derivatives of squaric acid with anti-proliferative activity | GPC BIOTECH AG (DE) | 2009-06-03 | — | — | EP | disclosed |
| US-20080200523-A1 | Derivatives of squaric acid with anti-proliferative activity | Valo Health, LLC | 2008-08-21 | — | — | US | disclosed |
| EP-1674457-A1 | Derivatives of squaric acid with anti-proliferative activity | GPC Biotech AG (DE) | 2006-06-28 | — | — | EP | disclosed |
| US-5696140-A | FOR TREATMENT OF ASTHMA, ALLERGIES, NERVOUS SYSTEM DISORDERS OR CANCER | LEO PHARMACEUTICAL PRODUCTS LTD. (DK) | 1997-12-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080200523-A1 | Derivatives of squaric acid with anti-proliferative activity | SQLE, FDFT1, DLD | DRD2 3634/4885DRD4 3529/4885DRD3 3156/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.